• Cadrenal Therapeutics outlined pivotal Phase 3 plans for CAD-1005 in heparin-induced thrombocytopenia following an End-of-Phase 2 meeting with FDA.
• Phase 2 results were already presented, showing fewer clot-related complications when CAD-1005 was added to standard anticoagulant care.
• Planned randomized, blinded, placebo-controlled Phase 3 trial targets about 120 patients across up to 50 centers worldwide.
• Primary readout will assess whether CAD-1005 reduces new or worsening clot events in lab-confirmed cases.
• Program timeline points to a potential NDA submission in 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300830PRIMZONEFULLFEED9709893) on April 30, 2026, and is solely responsible for the information contained therein.